Item 8.01 Other Events. On November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), in connection with the offering (the “Offering”), issuance and sale by the Company of 10,235,077…
Filed Nov 6, 2026Accepted Nov 6, 2026, 7:00 AM ESTCIK 1357874Accession 0001628280-26-071304
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), in connection with the offering (the “Offering”), issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the “Common Stock”), at a price of $7.75 per share and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its Common Stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of Common Stock less the $0.000005 per share exercise price for each pre-funded warrant. The Company estimates the net proceeds from the Offering will be approximately $116.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company and excluding any proceeds the Company may receive upon exercise of the pre-funded warrants being sold in the Offering. The Company intends to use the net proceeds of the Offering to fund the continued research and development of PBGENE-HBV and PBGENE-DMD, and for working capital and general corporate purposes.
The shares of Common Stock and pre-funded warrants are being sold pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-292478). A prospectus supplement relating to the offer and sale of the Common Stock and pre-funded warrants has been filed with the Securities and Exchange Commission. The closing of the Offering is expected to occur on November 6, 2026, subject to customary closing conditions.
The pre-funded warrants are exercisable at any time after their original issuance and are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock and holders of the pre-funded warrants also are entitled to participate on an as-exercised basis with respect to the Company’s stockholders. In the event of a fundamental transaction, a holder of the pre-funded warrants will be entitled to receive, upon exercise of the pre-funded warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction, without regard to any limitations on exercise contained in the pre-funded warrants. The pre-funded warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of Common Stock are entitled.
A holder of a pre-funded warrant will not be entitled to exercise any portion of such pre-funded warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates) to exceed 4.99% (or, at the holder’s option upon issuance, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrant. A holder may, upon notice to the Company, increase or decrease such beneficial ownership limitation, provided that it in no event exceeds 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, and any increase will not be effective until the 61st day after such notice is delivered to the Company.
The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.
The foregoing descriptions of the Underwriting Agreement and the form of pre-funded warrant are not complete and are qualified in their entirety by reference to the full text of the Underwriting Agreement and the form of pre-funded warrant, copies of which are filed, respectively, as Exhibit 1.1 and Exhibit 4.1 to this Current Report on Form 8-K and are incorporated by reference herein.
Latham & Watkins LLP, counsel to the Company, has issued an opinion regarding the validity of the shares of Common Stock, the shares of Common Stock issuable upon exercise of the pre-funded warrants and the pre-funded warrants offered and sold in the Offering. A copy of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K.
The Company issued a press release on November 5, 2026 announcing the pricing of the Offering, which press release is attached as Exhibit 99.1 to this report.
Filed exhibits (1)
EX-4.1 (by filename) ex41formofpre-fundedwarr.htm
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: November [6], 2026 PRECISION BIOSCIENCES, INC. Precision BioSciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [ ] shares of common stock, $0.000005 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.000005 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”), upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof (the “Original Issue Date”), subject to the following terms and conditions: 1. Definitions. For purposes of this Warrant,…